A fight over how long to protect certain high-end drugs from lower-cost imitators has emerged as the leading obstacle to negotiations aimed at completing the Trans-Pacific Partnership trade agreement.
from WSJ.com: US Business http://ift.tt/1he1vab
via IFTTT
No comments:
Post a Comment